Active Biotech doses first patient in amended tasquinimod myelofibrosis study
Ipsen's Phase III BOLD trial misses primary endpoint in biliary atresia
ArkBio completes Australian dosing in Phase I trial of influenza AFC drug AK0406
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
Bio-Thera Solutions reports first patient dosed in Phase 1 study of BAT8013
EU approves AstraZeneca's Etcamah combination for 1st-line ER-positive advanced breast cancer